Equillium, Inc. announced positive topline results on February 6, 2025, from its Phase 2 study evaluating itolizumab in patients with moderate to severe ulcerative colitis (UC). The study demonstrated clinical efficacy after 12 weeks of treatment.
Itolizumab achieved a clinical remission rate of 23.3% in UC patients, which compares favorably to 20.0% for adalimumab and 10.0% for placebo in the study. The drug also met the key secondary endpoint of endoscopic remission, with a rate of 16.7%, matching adalimumab and surpassing placebo's 6.7%.
These results highlight the therapeutic potential of itolizumab in a new indication, suggesting a broader application for the anti-CD6 monoclonal antibody. The data supports further development of itolizumab for inflammatory bowel diseases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.